Search - tctmd.com

Displaying 481 - 500 of 641

Sort: Relevancy | Date

News Daily News

First-In-Human Transcatheter Tricuspid Repair Feasible But Questions Remain

Michael O'Riordan

December 06, 2015

News Conference News VEITH 2015

Controversial Intravascular Therapy for Multiple Sclerosis Moves from Cath Lab to the OR

L.A. McKeown

November 24, 2015

News Industry News

NaviGate Cardiac Structures Inc. (“NCSI”) Reports First Patient Treated for Mitral Regurgitation (“MR”)

November 22, 2015

News Featured Fellow

Benjamin Z. Galper, MD, MPH

Yael L. Maxwell

November 15, 2015

News Industry News

First Pennsylvania Patient Treated in Next Generation Aortic Heart Valve Study

November 10, 2015

Presentation TCT 2015

New Noninvasive Methods for Assessing Valvular Heart Disease

Presenter: Jeroen J. Bax, Paul A. Grayburn

October 15, 2015

Presentation TCT 2015

Assessing Postdevice Paravalvular Aortic Regurgitation

Presenter: Jeroen J. Bax, Paul A. Grayburn, Rebecca T. Hahn

October 15, 2015

Presentation TCT 2015

What Defines Severe MR Post-AHA/ACC Guidelines?

Presenter: Jeroen J. Bax, Paul A. Grayburn

October 15, 2015

Presentation TCT 2015

Low-Flow, Low-Gradient Aortic Stenosis: How to Diagnosis, and Should We Treat?

Presenter: Jeroen J. Bax, Paul A. Grayburn, Philippe Pibarot

October 15, 2015

Presentation TCT 2015

LAA Closure vs Pharmacotherapy (Including NOACs) in a Patient With AF and Intermediate Risk of Bleeding Focused Commentary

Presenter: Martin B. Leon, Mark Reisman, Chet Rihal, Martin W Bergmann

October 15, 2015

Presentation TCT 2015

LAA Closure vs Pharmacotherapy (Including NOACs) in a Patient With AF and Intermediate Risk of Bleeding

Presenter: Martin B. Leon, Mark Reisman, Chet Rihal, Brij Maini

October 15, 2015

Presentation TCT 2015

Severe Functional MR + Symptoms With Slightly Reduced LVEF (45%) and Moderate Surgical Risk: Treatment Options Focused Commentary

Presenter: Martin B. Leon, Mark Reisman, Chet Rihal, Alec S. Vahanian

October 15, 2015

Presentation TCT 2015

Severe Functional MR + Symptoms With Slightly Reduced LVEF (45%) and Moderate Surgical Risk: Treatment Options

Presenter: Martin B. Leon, Mark Reisman, Chet Rihal, Olaf Franzen

October 15, 2015

Presentation TCT 2015

Severe AS + Symptoms in an 80-Year-Old With Low Surgical Risk: TAVR or Surgery?

Presenter: Martin B. Leon, Mark Reisman, Chet Rihal, Axel Linke

October 15, 2015

Presentation TCT 2015

Transcatheter Annuloplasty and Mitral Valve Replacement: Emerging Therapeutic Options

Presenter: Blase A. Carabello, Howard C. Herrmann

October 12, 2015

Presentation TCT 2015

Transcatheter Mitral Therapies in 2015: MitraClip in Trials and the Real World

Presenter: Blase A. Carabello, Howard C. Herrmann, Ted E. Feldman

October 12, 2015

Presentation TCT 2015

What Will TAVR Look Like in 2 and 10 Years From Now?

Presenter: Blase A. Carabello, Howard C. Herrmann, Duane S. Pinto

October 12, 2015

Presentation TCT 2015

TAVR 2015: Current Status

Presenter: Blase A. Carabello, Howard C. Herrmann, James B. Hermiller Jr

October 12, 2015

Presentation TCT 2015

Guideline Update: Whats New, and Whats Left Unsaid?

Presenter: Blase A. Carabello, Howard C. Herrmann

October 12, 2015

Presentation TCT 2015

Valvular Heart Disease: Aortic Valvuloplasty and TAVR

Presenter: Zoltan G. Turi, Rahul Sakhuja

October 12, 2015

Advertisement

First-In-Human Transcatheter Tricuspid Repair Feasible But Questions Remain

Controversial Intravascular Therapy for Multiple Sclerosis Moves from Cath Lab to the OR

NaviGate Cardiac Structures Inc. (“NCSI”) Reports First Patient Treated for Mitral Regurgitation (“MR”)

Benjamin Z. Galper, MD, MPH

First Pennsylvania Patient Treated in Next Generation Aortic Heart Valve Study

New Noninvasive Methods for Assessing Valvular Heart Disease

Assessing Postdevice Paravalvular Aortic Regurgitation

What Defines Severe MR Post-AHA/ACC Guidelines?

Low-Flow, Low-Gradient Aortic Stenosis: How to Diagnosis, and Should We Treat?

LAA Closure vs Pharmacotherapy (Including NOACs) in a Patient With AF and Intermediate Risk of Bleeding Focused Commentary

LAA Closure vs Pharmacotherapy (Including NOACs) in a Patient With AF and Intermediate Risk of Bleeding

Severe Functional MR + Symptoms With Slightly Reduced LVEF (45%) and Moderate Surgical Risk: Treatment Options Focused Commentary

Severe Functional MR + Symptoms With Slightly Reduced LVEF (45%) and Moderate Surgical Risk: Treatment Options

Severe AS + Symptoms in an 80-Year-Old With Low Surgical Risk: TAVR or Surgery?

Transcatheter Annuloplasty and Mitral Valve Replacement: Emerging Therapeutic Options

Transcatheter Mitral Therapies in 2015: MitraClip in Trials and the Real World

What Will TAVR Look Like in 2 and 10 Years From Now?

TAVR 2015: Current Status

Guideline Update: Whats New, and Whats Left Unsaid?

Valvular Heart Disease: Aortic Valvuloplasty and TAVR

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content